Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Curr Treat Options Psychiatry. 2020 Jul 28;7(3):375–399. doi: 10.1007/s40501-020-00221-z

Fig. 6.

Fig. 6

Prevalence of buprenorphine versus buprenorphine-naloxone use through the perinatal period by pregnancy or postpartum time interval (N=240) with teal column representing buprenorphine monoproduct and cream column representing buprenorphine-naloxone combination product. Use of both varied throughout the pregnancy period, and the majority of participants used the combination product throughout postpartum.